🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Choose wisely and safe patients from unnecessary tests. 8/649 relapses in non-high GIST! Thank you for the great collaboration Kjetil Boye and the Gothenburg group! Karolinska Institutet Karolinska Univ.sjuk Svenska Sällskapet för Medicinsk Forskning

Already 100 attendees registered for FORTRESS 2024 in Leuven - only a few places left, as we are limiting the number of participants at the workshop! Check our webpage for all relevant details: kuleuven.be/fortress

#Sarcoma #MiniOrals ongoing right now at #ESMO23. Lots of discussions on #QoL, #desmoids, #GIST novel therapies and #translationalResearch with #ctDNA. Come join us if you can or find the time to review the recordings! chaired by Kjetil Boye Piotr Rutkowski Nadia Hindi

#ESMO23 special symposium focusing on new mechanisms and drugs for the treatment of patients with #Sarcoma Robin Lewis Jones @seppobauer Tom Wei-Wu Chen Kjetil Boye and Marta Sbaraglia

Excited to be touching down among the beautiful green fields & rolling hills I know and ❤️ for an extra special #CTOS2023 in 🇮🇪 this year 🤗 Delighted for 🌎 #team #sarcoma to get to share in 🇮🇪 beauty & culture in the days to come #CTOSTweeTOS Tourism Ireland Wild Atlantic Way

Popular poster session at the annual sarcoma meeting #CTOS2023. Together with Kjetil Boye presenting our results from our #GIST studies on chromosomal complexity Norwegian Sarcoma Group ous-research

We seek a new Unit Leader for our Preclinical Proton Therapy and Imaging Unit at the Institute for Cancer Research, Oslo University Hospital. In connection with establishing a new proton therapy center at our Hospital. Deadline 1st December finn.no/job/management…

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial | Nature Medicine nature.com/articles/s4159…

Two postdoctoral research fellow positions in cancer genomics and bioinformatics are available at my group at the Institute for Cancer Research, Oslo University Hospital. #sarcoma stratification and resistance. Centre for Cancer Cell Reprogramming finn.no/job/fulltime/a… finn.no/job/fulltime/a…

Day 1 of the annual Norwegian Sarcoma Group Meeting in beautiful Tromsø 🗻☀️More than 1️⃣0️⃣0️⃣ participants from different disciplines! Norwegian Sarcoma Group Joachim Thorkildsen Oslounivsykehus UNN Haukeland St. Olavs hospital

📱 RISK prediction in localized #sarcoma There are 2 apps with high lever of agreement that can be downloaded and used in the clinic: 1️⃣ PERSARC 🔗 sites.google.com/view/daspo/pro… 2️⃣ SARCULATOR 🔗 sarculator.com 📸 Kjetil Boye #ESMO24 #ESMOAmbassadors

Great science on Day 2 of the #GISTTSummit2024 - many thanks to the organizers @seppobauer & J. Fletcher for bringing us together from all over the world in this unique setting at #oktogonessen to foster collaboration in the #Sarcoma field!

Brightline-1 provides the sarcoma community with a new, reliable progression-free survival benchmark of 7.16 months for single agent doxorubicin in patients with inoperable, locally advanced or metastatic, chemo-naive dedifferentiated liposarcoma. Schöffski et al. CTOS 2024

Hot off the press - 'Genetic predisposition in sarcomas: clinical implications and management'. Very happy to have been a co-author of this paper. sciencedirect.com/science/articl…

🧬 Genetic Predisposition in Sarcoma Up to 20% #sarcoma may be assoc. with predisposition genes In our 📝 we review evidence on genetic predis. & how it may influence Rx decisions & management inc. surgery, radiotherapy, systemic Rx & surveillance 1/4 thelancet.com/journals/eclin…

CTOS President Silvia Stacchiotti is inviting everyone to join the Annual Meeting in Boca Raton and celebrate 30th Anniversary of the Society! Get ready and prepare your abstracts! Especially on the #sarcoma of the year 🌟#chondrosarcoma #CTOS2025 #CTOSTweeTOS

EP300::VGLL3 #rhabdomyosarcoma: a potential distinct indolent adult RMS subtype 🚨Think of this emerging subtype if: ✔️Male, aged 30-60 ✔️ Spindle cell / sclerosing #RMS 👅 of the tongue 🙌🏻 Appear indolent with good outcomes in all reported cases esmorarecancers.org/article/S3050-

For the first time, we’ve set benchmark values for surgery in primary retroperitoneal liposarcoma (WDLPS/DDLPS). 15 expert centres. 22 key metrics. A new standard for measuring surgical quality. Presented at #CTOS2024. Great collaborative effort from TARPSWG.